Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Cited by (999)

Items 701–800 of 999

1. Ligand and Substrate Migration in Human Indoleamine 2,3-Dioxygenase
   Elena Nickel, Karin Nienhaus, Changyuan Lu, Syun‐Ru Yeh, Gerd Ulrich Nienhaus · 2009 · Journal of Biological Chemistry
2. Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances
   Mikolaj M. Krupa, Tomasz Pienkowski, Anna Tankiewicz‐Kwedlo, Tomasz Łysoń · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
3. Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics
   Kassandra M. Coyle, Lindsey G. Hawke, Mark L. Ormiston · 2023 · Cancers
4. Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment
   Parviz Azimnasab-sorkhabi, Maryam Soltani-asl, Túlio Teruo Yoshinaga, M.L. Dagli, Cristina de Oliveira Massoco, José Roberto Kfoury · 2023 · Molecular Biology Reports
5. Effects of IFN- γ And Stat1 on Gene Expression, Growth, And Survival in Non-Small Cell Lung Cancer Cells
   Jiannong Li, Bin Yu, Lanxi Song, Steven A. Eschrich, Eric B. Haura · 2007 · Journal of Interferon & Cytokine Research
6. BRUSELAS: HPC Generic and Customizable Software Architecture for 3D Ligand-Based Virtual Screening of Large Molecular Databases
   Antonio Jesús Banegas‐Luna, José P. Cerón‐Carrasco, Savíns Puertas Martín, Horacio Pérez‐Sánchez · 2019 · Journal of Chemical Information and Modeling
7. Altered Tryptophan Metabolism as a Paradigm for Good and Bad Aspects of Immune Privilege in Chronic Inflammatory Diseases
   Lingqian Li, Lei Huang, Henrique de Paula Lemos, Mario R. Mautino, Andrew L. Mellor · 2012 · Frontiers in Immunology
8. Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod
   Zuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, Mason Webb, Eslam T. Mohamed, Okoev Gg, Adelaida Matevosyan, Rajeev Kumar Shrimali, Rasha Abu Eid, Scott A. Hammond et al. · 2018 · Cancer Immunology Research
9. Addendum: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury
   Alexei Degterev, Zhihong Huang, Michael Boyce, Yaqiao Li, Prakash G. Jagtap, Noboru Mizushima, Gregory D. Cuny, Timothy John Mitchison, Michael A. Moskowitz, Junying Yuan · 2013 · Nature Chemical Biology
10. Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
    Xi Jin Xu, Jie Ren, Yinghe Ma, Hongting Liu, Quanjin Rong, Yifan Feng, Yameng Wang, Yu Cheng, Ruijia Ge, Zhiyu Li et al. · 2019 · Journal of Enzyme Inhibition and Medicinal Chemistry
11. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism
    Véronique Trézéguet, Hala Fatrouni, Aksam J. Merched · 2021 · Cells
12. Effect of metabolism on the immune microenvironment of breast cancer
    Yingming Zhou, Hu Wang, Yi Luo, Biguang Tuo, Xuemei Liu, Taolang Li · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
13. Low dose Zebularine treatment enhances immunogenicity of tumor cells
    Hua Liu, Zhong‐Tian Xue, Hans Olov Sjögren, Leif G. Salford, Bengt Widegren · 2007 · Cancer Letters
14. Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058
    Jun‐Pil Jang, Jae‐Hyuk Jang, Mijin Oh, Sangkeun Son, Seung Min Kim, Hye-Min Kim, Kee‐Sun Shin, Hyuncheol Oh, Nak‐Kyun Soung, Young‐Soo Hong et al. · 2013 · The Journal of Antibiotics
15. Altered tryptophan metabolism in human meningioma
    Noble Kumar Talari, Manas Kumar Panigrahi, Sailaja Madigubba, Sundaram Challa, Prakash Babu Phanithi · 2016 · Journal of Neuro-Oncology
16. Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer
    Liyan Lao, Siting Fan, Erwei Song · 2017 · Advances in experimental medicine and biology
17. Eicosapentaenoic acid reduces indoleamine 2,3-dioxygenase 1 expression in tumor cells
    Chih-Chiang Wang, Chih‐Jen Yang, Li-Hsien Wu, Han-Chen Lin, Zhi‐Hong Wen, Che‐Hsin Lee · 2018 · International Journal of Medical Sciences
18. AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders
    Sharmin Esmailzadeh, Xiaoyan Jiang · 2011 · Oncotarget
19. Dendritic cell immunotherapy for breast cancer
    Alberto Pinzón‐Charry, Christopher Schmidt, José Alejandro López · 2006 · Expert Opinion on Biological Therapy
20. Bin1 Interacts with and Restrains the DNA End-Binding Protein Complex Ku
    Ramalingam, Arivudainambi, Farmer, George E., Stamato, Thomas, Prendergast, George C. · 2007 · Cell Cycle
21. Bin1 Attenuation Suppresses Experimental Colitis by Enforcing Intestinal Barrier Function
    Mee Young Chang, Janette Boulden, Mary Carmen Valenzano, Alejandro Peralta Soler, Alexander J. Muller, James M. Mullin, George C. Prendergast · 2012 · Digestive Diseases and Sciences
22. Clinical Development of Combination Strategies in Immunotherapy: are We Ready for More Than One Investigational Product in an Early Clinical Trial?
    José Luis Perez‐Gracia, Pedro Berraondo, Iván Martínez‐Forero, Carlos Alfaro, Natalia Suárez, Alfonso Gúrpide, Bruno Sangro, Sandra Hervás‐Stubbs, Carmen Ochoa, José Antonio Melero et al. · 2009 · Immunotherapy
23. Eleven undescribed alkaloids from the rhizomes of Sinomenium acutum and their IDO1 and TDO inhibitory activities
    Ran Bi, Xinni Yang, Haofeng Zhou, Li‐Yan Peng, Jiangxin Liu, Qin‐Shi Zhao · 2022 · Phytochemistry
24. Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy
    Nayeon Shim, Hanhee Cho, Seong Ik Jeon, Kwangmeyung Kim · 2023 · Journal of Pharmaceutical Investigation
25. The role of metabolic reprogramming in immune escape of triple-negative breast cancer
    Ruochen Bao, Hongtao Qu, Baifeng Li, Kai Cheng, Yandong Miao, Jiangtao Wang · 2024 · Frontiers in Immunology
26. Development of 1-N-11C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan
    Lin Xie, Jun Maeda, Katsushi Kumata, Joji Yui, Yiding Zhang, Akiko Hatori, Nobuki Nengaki, Hidekatsu Wakizaka, Masayuki Fujinaga, Tomoteru Yamasaki et al. · 2015 · Scientific Reports
27. Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach
    Masaichi Ogawa, Michiaki Watanabe, Takuo Hasegawa, Kohei Ichihara, Kazuhiko Yoshida, Katsuhiko K. Yanaga · 2017 · Molecular and Clinical Oncology
28. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS
    Maysaa Abdulla, Andrei Alexsson, Christer Sundström, Claes Ladenvall, Larry Mansouri, Cecilia Lindskog, Mattias Berglund, Lucia B. Cavelier, Gunilla Enblad, Peter Hollander et al. · 2021 · Acta Oncologica
29. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies
    Jack G. Shi, Kevin Bowman, Xuejun Chen, Janet E. Maleski, Lance Howard Leopold, Swamy Yeleswaram · 2016 · The Journal of Clinical Pharmacology
30. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases
    Stefan Stremitzer, Yu Sunakawa, Wei Yan Zhang, Dongyun Yang, Y Ning, Sebastian Stintzing, Ana Sebio, Shinichi Yamauchi, S. Matsusaka, Rita Elie El-Khoueiry et al. · 2015 · The Pharmacogenomics Journal
31. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects
    C-A Chen, M‐C Chang, W-Z Sun, Y-L Chen, Y-C Chiang, C-Y. Hsieh, S M Chen, Po‐Ni Hsiao, W-F Cheng · 2009 · Gene Therapy
32. Immune system modulation in patients with malignant and benign breast disorders: tryptophan degradation and serum neopterin.
    G. Girgin, Tevfik Tolga Sahin, D. Fuchs, H. Kasuya, O. Yuksel, E. Tekin, T. Baydar · 2009 · International Journal of Biological Markers
33. Indoleamine-2,3-dioxygenase: An important controller in maintaining mesenchymal stem cell-mediated immunomodulatory homeostasis
    Yufei Hui, Xue Jiao, Li Yang, Dejin Lu, Yanbo Han, Wen Yang, Yanli Cao, Yuxi Miao, Shiqiang Gong, Minjie Wei · 2025 · Acta Pharmaceutica Sinica B
34. Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond
    Mads Hald Andersen · 2026 · Signal Transduction and Targeted Therapy
35. Inter‐ and intrapatient heterogeneity of indoleamine 2,3‐dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
    T. Gide, B. Allanson, A. Menzies, P. Ferguson, J. Madore, R. Saw, John F. Thompson, G. Long, J. Wilmott, R. Scolyer · 2019 · Histopathology
36. The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas
    Melissa R. Chambers, R. Timothy Bentley, David K. Crossman, Jeremy B. Foote, Jennifer W. Koehler, James M. Markert, Nidal Bassam Omar, Simon R. Platt, Dwight Mitchell Self, Andy Shores et al. · 2020 · Frontiers in Surgery
37. A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy
    Na Wang, Zhigang Wang, Zoufeng Xu, Xianfeng Chen, Guangyu Zhu · 2018 · Angewandte Chemie
38. Metabolic reprograming of cancer as a therapeutic target
    Tatsuhiko Furukawa, Sho Tabata, Kentaro Minami, Masatatsu Yamamoto, Kohichi Kawahara, Akihide Tanimoto · 2022 · Biochimica et Biophysica Acta (BBA) - General Subjects
39. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy
    Xun Wang, Bin Yan, Hugang Li, Jianlan Yuan, Jingyi Guo, Siyao Wang, Penggao Dai, Xiaoli Liu · 2024 · ACS Applied Materials & Interfaces
40. SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells
    Peng Zhang, Guanmin Jiang, Jian Gao, Lingling Li, Jun Du, Xingyuan Jiao · 2012 · Oncology Reports
41. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
    Chenggang Yang, Yongchun Zhou, Lijuan Zhang, Congguo Jin, Mei Li, Lijuan Ye · 2015 · Europe PMC (PubMed Central)
42. Methodology of drug screening and target identification for new necroptosis inhibitors
    Pengchao Pan, Zhenyu Cai, Chunlin Zhuang, Xiaofei Chen, Yifeng Chai · 2018 · Journal of Pharmaceutical Analysis
43. Prognostic and clinico-pathological significance of BIN1 in breast cancer
    Subbroto Kumar Saha, Md. Ashraful Kader, Kazi Abdus Samad, Krishno Chandra Biswas, Md. Ataur Rahman, Md. Anowar Khasru Parvez, Md. Shahedur Rahman · 2020 · Informatics in Medicine Unlocked
44. Kynurenine 3‐monooxygenase ( KMO ), and signal transducer and activator of transcription 3 ( STAT3 ) expression is involved in tumour proliferation and predicts poor survival in canine melanoma
    I‐Li Liu, Ting‐Fang Chung, Wei‐Hsiang Huang, Chia‐Hui Hsu, Cheng‐Chi Liu, Yi‐Han Chiu, Kuo‐Chin Huang, Albert Taiching Liao, Chen‐Si Lin · 2020 · Veterinary and Comparative Oncology
45. The Kynurenine Pathway
    Yiquan Chen, Gilles Guillemi · 2012 · InTech eBooks
46. Identification of Substituted 1 H ‐Indazoles as Potent Inhibitors for Immunosuppressive Enzyme Indoleamine 2,3‐Dioxygenase 1
    Nirmalya Pradhan, Saurav Sekhar Paul, Suman Jyoti Deka, Ashalata Roy, Vishal Trivedi, Debasis Manna · 2017 · ChemistrySelect
47. Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer
    Soudeh Ghafouri‐Fard, Zahra Taherian‐Esfahani, Sepideh Dashti, Vahid Kholghi Oskooei, Mohammad Naser Taheri, Majid Samsami · 2020 · Experimental and Molecular Pathology
48. Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options
    Ayşe Başak Engin, Atilla Engin · 2024 · Advances in experimental medicine and biology
49. Calcium Channel Blocker Lacidipine Promotes Antitumor Immunity by Reprogramming Tryptophan Metabolism
    Yuwen Sheng, Chong Qiao, Zhonghui Zhang, Xiaoke Shi, Linhan Yang, Ruiying Xi, Jialing Yu, Wanli Liu, Guolin Zhang, Fei Wang · 2024 · Advanced Science
50. Kynurenine pathway enzyme KMO in cancer progression: A tip of the Iceberg
    So‐Yeon Park, Jeong‐Seok Nam · 2020 · EBioMedicine
51. Insights into Therapy: Tryptophan Oxidation and HIV Infection
    Michael F. Murray · 2010 · Science Translational Medicine
52. Determination of Kynurnine and Tryptophan, Biomarkers of Indoleamine 2,3-Dioxygenase by LC–MS/MS in Plasma and Tumor
    Wenyan Wang, Xuhui Zhuang, Wenrong Liu, Lina Dong, Heyuan Sun, Guangying Du, Liang Ye · 2018 · Bioanalysis
53. Modulation of Tumor Tolerance in Primary Central Nervous System Malignancies
    Theodore S. Johnson, David H. Munn, Bernard L. Maria · 2012 · Clinical and Developmental Immunology
54. Contribution of IDO to human respiratory syncytial virus infection
    Felipe M. Benavente, Jorge A. Soto, Magdalena S. Pizarro-Ortega, Karen Böhmwald, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis · 2019 · Journal of Leukocyte Biology
55. CpG‐related SNPs in the MS4A region have a dose‐dependent effect on risk of late–onset Alzheimer disease
    Yiyi Ma, Gyungah Jun, Jaeyoon Chung, Xiaoling Zhang, Brian W. Kunkle, Adam Christian Naj, Charles C. White, David Alan Bennett, Philip L. De Jager, Richard P Mayeux et al. · 2019 · Aging Cell
56. Harnessing sulfur-doped carbon nanodots conjugated with IDO inhibitors act as a dual-mode breast cancer immunotherapy
    Roberta Cillari, Rita C. Acúrcio, Andreia Pereira Barateiro, Helena F. Florindo, Nicolò Mauro, Gennara Cavallaro · 2025 · Journal of Controlled Release
57. IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
    Selcen Öztürk, Verena Kalter, Philipp M. Roessner, Murat Sünbül, Martina Seiffert · 2021 · Cancers
58. Heterogeneity of the tumor immune microenvironment and clinical interventions
    Zheng Jin, Qin Zhou, Jianan Cheng, Qingzhu Jia, Bo Zhu · 2023 · Frontiers of Medicine
59. Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges
    Rafael L. Bejar, Ramon Velasquez Tiu, Mikkael Aaron Sekeres, Rami S. Komrokji · 2013 · American Society of Clinical Oncology Educational Book
60. Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth
    Sabine Pfeifer, Martin Schreder, Arnold Bolomsky, Sebastian Graffi, Dietmar Fuchs, Surinder Singh Sahota, Heinz Ludwig, Niklas Zojer · 2012 · Journal of Cancer Research and Clinical Oncology
61. Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase
    Shixian Hua, Feihong Chen, Shaohua Gou · 2019 · European Journal of Medicinal Chemistry
62. Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas
    Jordan A. Stinson, Allison M. Sheen, Noor Momin, Jordan Hampel, Rebecca Bernstein, Rebecca L. Kamerer, Bahaa A. Fadl-Alla, Jonathan Samuelson, Elizabeth Fink, Timothy M. Fan et al. · 2023 · Clinical Cancer Research
63. IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages
    Xiao Chen, Jie Yao, Mengyu Zhang, Rui Li, Xiao Liu, Yi-Qing Qu · 2023 · International Journal of General Medicine
64. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function
    Sunil Thomas, Joanna M. Mercado, James B. DuHadaway, Kate DiGuilio, James M. Mullin, George C. Prendergast · 2015 · Digestive Diseases and Sciences
65. Specific In Situ Detection of Murine Indoleamine 2, 3‐ D ioxygenase
    Sunil Thomas, James B. DuHadaway, George C. Prendergast, Lisa D. Laury‐Kleintop · 2013 · Journal of Cellular Biochemistry
66. Tumor-associated macrophages (TAMs) as new target in anticancer therapy
    Alberto Mantovani, Chiara Porta, Luca Rubino, Paola Allavena, Antonio Sica · 2006 · Drug Discovery Today Therapeutic Strategies
67. Marine Bioactive Compounds from Cnidarians
    Joana Rocha, Ricardo Calado, Miguel Costa Leal · 2015 · Springer eBooks
68. Mutations in components of antiviral or microbial defense as a basis for breast cancer
    Bernard Friedenson · 2013 · Functional & Integrative Genomics
69. Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
    Jonathan L. Messerschmidt, Prianka Bhattacharya, Gerald L. Messerschmidt · 2017 · Current Oncology Reports
70. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases
    Sergio Rutella, Raimondo DE CRISTOFARO, Gianfranco Ferraccioli · 2009 · Human Immunology
71. Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas
    April C.L. Bostian, Robert Lawton Eoff · 2016 · Chemical Research in Toxicology
72. Heme-based dioxygenases: Structure, function and dynamics
    Zachary Geeraerts, Izumi Ishigami, Yuan Gao, Syun‐Ru Yeh · 2024 · Journal of Inorganic Biochemistry
73. Suppression of Immunodominant Antitumor and Antiviral CD8+ T Cell Responses by Indoleamine 2,3-Dioxygenase
    Mateusz Rytelewski, Courtney Erin Meilleur, Maryam Atef Yekta, Peter Anthony Szabo, Nitan Garg, Todd D. Schell, Anthony M. Jevnikar, Shayan Sharif, Bhagirath Singh, S. M. Mansour Haeryfar · 2014 · PLoS ONE
74. The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth
    Babak Baban, William Todd Penberthy, Mahmood S. Mozaffari · 2010 · The EPMA Journal
75. Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model
    Elisa Wirthgen, Ellen Kanitz, Margret Tuchscherer, Armin Tuchscherer, Grażyna Domańska, Werner Weitschies, Anne Seidlitz, Eberhard Scheuch, Winfried Otten · 2015 · EXPERIMENTAL ANIMALS
76. Substrate binding in human indoleamine 2,3-dioxygenase 1: A spectroscopic analysis
    Karin Nienhaus, Elena Nickel, Gerd Ulrich Nienhaus · 2017 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
77. Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas
    Tvrtko Hudolin, Chantal Mengus, Julie Coulot, Željko Kaštelan, Ahmad El‐Saleh, Giulio C. Spagnoli · 2017 · Anticancer Research
78. Discovery of potent indoleamine 2,3-dioxygenase (IDO) inhibitor from alkaloids in Picrasma quassioides by virtual screening and in vitro evaluation
    Ning Wang, Jie Zhang, Qiao Li, Hui Zhong Xu, Geng Chen, Zhiyong Li, Difa Liu, Xin Yang · 2019 · Fitoterapia
79. Discovery of IDO1 and DNA dual targeting antitumor agents
    Kun Fang, Shanchao Wu, Guoqiang Dong, Ying Wu, Shuqiang Chen, Jianhe Liu, Wei Wang, Chunquan Sheng · 2017 · Organic & Biomolecular Chemistry
80. Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1
    Jiali Wang, Yunlong Jia, Tianxu Liu, Xinyan Liu, Shuxian Yin, Jiaqi Chen, Xiaoqing Xu, Yi Zhang, Lihua Liu · 2025 · Journal of Experimental & Clinical Cancer Research
81. Die hard: necroptosis and its impact on age-dependent neuroinflammatory diseases
    Kaitlan Smith, Meagan Colie, Trinity Moore, Jonathan Cummings Schisler · 2024 · Frontiers in Cell Death
82. Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies
    Karl O. Holmberg, Anna Borgenvik, Miao Zhao, G Giraud, Fredrik J. Swartling · 2024 · Cancers
83. Necroptosis: a significant and promising target for intervention of cardiovascular disease
    Yanwei Ji, Xinyu Wen, He-Peng Tang, Wating Su, Zhongyuan Xia, Shaoqing Lei · 2025 · Biochemical Pharmacology
84. Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy
    Alisha Holtzhausen, Fei Linda Zhao, Kathy S. Evans, Brent Allen Hanks · 2014 · Frontiers in Immunology
85. Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents
    Ngo Xuan Hoang, Van-Hai Hoang, Thi-Thu-Trang Luu, Hung Nguyen Luu, Thien Ngo, Duong Van Hieu, Nguyen Huu Long, Le Viet Anh, Sơn Tùng Ngô, Yen Thi Kim Nguyen et al. · 2020 · RSC Advances
86. Comprehensive polar metabolomics and lipidomics profiling discriminates the transformed from the non-transformed state in colon tissue and cell lines
    Caroline Rombouts, Margot De Spiegeleer, Lieven Van Meulebroek, Lynn Vanhaecke, Winnok Harald De Vos · 2021 · Scientific Reports
87. High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome
    Wenjuan Ma, Hao Duan, Rongxin Zhang, Xing Wang, Haineng Xu, Qianghua Zhou, Li Zhang · 2019 · Journal of Cancer
88. Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
    Lin Xie, Kuan Hu, Yanhong Duo, Takashi Shimokawa, Katsushi Kumata, Yiding Zhang, Cuiping Jiang, Lulu Zhang, Nobuki Nengaki, Hidekatsu Wakizaka et al. · 2021 · Journal for ImmunoTherapy of Cancer
89. Turn Off the IDO: Will Clinical Trials Be Successful?
    Sergey V. Novitskiy, Harold L. Moses · 2012 · Cancer Discovery
90. IDO and outcomes in ovarian cancer
    Brad H. Nelson · 2009 · Gynecologic Oncology
91. Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
    Sahar Tahaghoghi-Hajghorbani, Mona Yazdani, Amin Reza Nikpoor, Mahdi Hatamipour, Abolghasem Ajami, Mahmoud Reza Jaafari, Ali Badiee, Alireza Rafiei · 2023 · Scientific Reports
92. Synthesis and Biological Evaluation of Novel 2-Amino-1,4-Naphthoquinone Amide-Oxime Derivatives as Potent IDO1/STAT3 Dual Inhibitors with Prospective Antitumor Effects
    Ri-Zhen Huang, Qiaoling Liang, Xiao-Teng Jing, Ke Wang, Huiyong Zhang, Heng‐Shan Wang, Xian‐Li Ma, Jian-Hua Wei, Ye Zhang · 2023 · Molecules
93. Dual‐Targeting Nanoliposome Improves Proinflammatory Immunomodulation of the Tumor Microenvironment
    Zili Gu, Candido G. Da Silva, Sen Ma, Qi Liu, Timo Schomann, FERRY A. OSSENDORP, Luis Javier Cruz · 2023 · Advanced Healthcare Materials
94. Necroptosis in Pneumonia: Therapeutic Strategies and Future Perspectives
    Xiuzhen Mei, Yuchen Zhang, Shu Wang, Hui Wang, Rong Chen, Ke Ma, Yue Yang, Ping Jiang, Zhixin Feng, Chao Zhang et al. · 2024 · Viruses
95. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance
    Delia Hoffmann, Tereza Dvořáková, Florence Schramme, Vincent Stroobant, Benoit J. Van den Eynde · 2020 · Frontiers in Immunology
96. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer
    Yiqun Li, Wenjie Wang, Danyun Wang, Liuchao Zhang, Xizhi Wang, Jia He, Lei Cao, Kang Li, Hongyu Xie · 2022 · Genes
97. Immunotherapy for Melanoma
    Justin T. Moyers, Isabella C. Glitza Oliva · 2021 · Advances in experimental medicine and biology
98. Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
    Guanyou Huang, Yao-Ying Zeng, Pei‐Yan Liang, Zhou Congrong, Shuyun Zhao, Xiu−Yan Huang, Ling‐Fei Wu, Xian‐Hui He · 2012 · International Journal of Molecular Sciences
99. The immunoregulatory function of indoleamine 2, 3 dioxygenase and its application in allotransplantation.
    Reza B. Jalili, Farshad Forouzandeh, Mohammad Ali Bahar, Aziz Ghahary · 2007 · PubMed
100. Chemical Tools and Materials for Biological/Medicinal Applications
     Xuehai Yan, Jan C. M. van Hest · 2018 · Chemistry - An Asian Journal